

# Randomised Controlled Trial of Intravitreal Triamcinolone in Patients with Diabetic Macular Oedema Refractory to Laser Treatment

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/04/2011	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr S A Vernon

**Contact details**  
B Floor  
The Eye & ENT Unit  
University Hospital  
Nottingham  
United Kingdom  
NG7 2UH  
+44 (0)115 924 9924  
stephen.vernon@nuh.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

N0192133909

# Study information

## Scientific Title

### Study objectives

Does principal intravitreal injection of triamcinolone help in treating diabetic patients with clinically significant macular oedema that is refractory to the conventional focal or grid laser photocoagulation?

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Not Specified

## Participant information sheet

### Health condition(s) or problem(s) studied

Eye Diseases: Diabetic macular oedema

### Interventions

1. Intravitreal injection of triamcinolone
2. Placebo

As of March 2008: trial abandoned due to poor recruitment.

### Intervention Type

Drug

### Phase

Not Specified

**Drug/device/biological/vaccine name(s)**

Triamcinolone

**Primary outcome measure**

Pre-injection and then month 1, 3 and 6

1. Best corrected visual acuity (logarithm of the minimum angle of resolution [logMAR]) at each visit. A change in either direction of 10 letters on the logMAR chart would be considered significant
2. Near vision tested with a standard add on each visit, with time taken to read the standard N paragraph and the number of mistakes made
3. Intra-ocular pressure at each visit - measured by standard applanation tonometry

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

28/11/2003

**Completion date**

01/07/2006

**Reason abandoned (if study stopped)**

Lack of staff/facilities/resources

## Eligibility

**Key inclusion criteria**

Not provided at time of registration

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

28/11/2003

**Date of final enrolment**

01/07/2006

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

### B Floor

Nottingham

United Kingdom

NG7 2UH

# Sponsor information

## Organisation

Department of Health

## Sponsor details

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

## Sponsor type

Government

## Website

<http://www.dh.gov.uk/Home/fs/en>

# Funder(s)

## Funder type

Government

## Funder Name

Queen's Medical Centre University Hospital NHS Trust (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration